Miranza: Comprehensive Company Profile

Background

Overview

Miranza is a leading group specializing in ocular wellness, operating a network of ophthalmology centers across Spain, Andorra, and Portugal. The company is dedicated to providing accessible, high-quality eye care through a combination of research, prevention, and treatment. Miranza is part of the Veonet network, which includes prominent eye care groups in Europe, collectively serving over 2 million patients annually.

Mission and Vision

Miranza's mission is to make medical excellence in ophthalmology accessible to all individuals seeking eye and overall well-being. The company aims to lead in eye care by focusing on research, prevention, and treatment, fostering a healthier future for its patients.

Primary Area of Focus

The company specializes in comprehensive eye care services, including clinical diagnosis, genetic counseling, treatment, support, and research in eye health. Miranza operates a network of centers with high-quality standards and homogeneous protocols, offering national coverage to both local and international patients.

Industry Significance

As part of the Veonet network, Miranza contributes to a significant presence in the European ophthalmology sector, with over 250 clinics across five countries. This extensive network collectively serves more than 2 million patients annually, highlighting Miranza's role in advancing eye care services in the region.

Key Strategic Focus

Core Objectives

Expansion and Growth: Miranza aims to expand its network by acquiring new clinics and integrating them into its operations, thereby increasing its market presence.

Operational Efficiency: The company focuses on optimizing its operations to enhance service delivery and patient satisfaction.

International Collaboration: Miranza seeks to establish strategic partnerships to elevate eye care standards and share expertise globally.

Specific Areas of Specialization

Advanced Ophthalmic Treatments: Miranza offers specialized services in areas such as cataract surgery, retinal treatments, and refractive surgery.

Genetic Diagnosis and Research: The company provides genetic counseling and conducts research in gene therapies for eye conditions lacking current treatments.

Key Technologies Utilized

State-of-the-Art Surgical Equipment: Miranza employs advanced surgical tools and technologies to perform complex eye procedures.

Telemedicine Services: The company offers teleconsultation services, allowing patients to access care remotely.

Primary Markets Targeted

Spain: With a significant number of clinics, Spain remains Miranza's primary market.

Portugal: The company has expanded into Portugal, acquiring clinics in Porto and Guimarães.

Andorra: Miranza operates a clinic in Andorra, contributing to its regional presence.

Financials and Funding

Funding History

Acquisition by Veonet: In September 2022, Miranza was acquired by Veonet, a leading European ophthalmology group, for €250 million.

Recent Financial Performance

2024 Revenue: Miranza reported a revenue of €110 million in 2024, marking a 10% increase from the previous year.

Utilization of Capital

The capital from the acquisition and revenue growth has been utilized for:

Clinic Expansion: Acquiring new clinics in Spain and Portugal to broaden the network.

Operational Enhancements: Investing in advanced medical equipment and technologies to improve service quality.

Research and Development: Funding research initiatives, particularly in genetic diagnosis and gene therapies for eye conditions.

Pipeline Development

Key Pipeline Candidates

Gene Therapies: Miranza is involved in research for gene therapies targeting eye conditions without current treatments.

Advanced Surgical Techniques: The company is developing and refining surgical methods to enhance patient outcomes.

Stages of Development

Clinical Trials: Ongoing trials for gene therapies and new surgical techniques.

Regulatory Approvals: Seeking approvals for new treatments and technologies.

Target Conditions

Inherited Retinal Diseases: Focusing on genetic disorders affecting the retina.

Age-Related Macular Degeneration: Developing treatments for this common cause of vision loss.

Anticipated Milestones

2025: Expected completion of Phase II trials for gene therapy candidates.

2026: Anticipated launch of new surgical techniques in select clinics.

Technological Platform and Innovation

Proprietary Technologies

Genetic Diagnostic Tools: Miranza utilizes proprietary tools for diagnosing genetic eye conditions.

Advanced Surgical Equipment: The company employs state-of-the-art equipment for complex eye surgeries.

Significant Scientific Methods

Genetic Counseling: Providing genetic counseling services to patients with hereditary eye conditions.

Telemedicine: Offering teleconsultation services to enhance accessibility.

Leadership Team

Key Executives

Ramón Berra: General Director of Miranza, leading the company's strategic direction and operations.

Dr. Federico Alonso Aliste: Director of Tecnolaser Clinic Vision, a recent addition to Miranza's network.

Professional Backgrounds

Ramón Berra: With extensive experience in ophthalmology management, Berra has been instrumental in Miranza's growth and integration into the Veonet network.

Dr. Federico Alonso Aliste: A specialist in advanced eye surgery and laser treatments, Aliste brings over two decades of expertise to Miranza.

Key Contributions

Ramón Berra: Oversaw the acquisition by Veonet and the subsequent expansion into Portugal.

Dr. Federico Alonso Aliste: Led the integration of Tecnolaser Clinic Vision into Miranza's operations.

Leadership Changes

Recent Appointments

Dr. Federico Alonso Aliste: Appointed as Director of Tecnolaser Clinic Vision following its acquisition in 2025.

Competitor Profile

Market Insights and Dynamics

Market Size: The European ophthalmology market is substantial, with a growing demand for specialized eye care services.

Growth Potential: Opportunities exist in expanding services to underserved regions and integrating advanced technologies.

Competitor Analysis

Ober Scharrer Gruppe (OSG): A leading ophthalmology group in Germany, known for its extensive network and advanced treatments.

Eyescan: A prominent eye care provider in the Netherlands, recognized for its innovative approaches.

VISTA: A Swiss ophthalmology group offering comprehensive eye care services.

SpaMedica: A UK-based eye care provider with a focus on patient-centered services.

Strategic Collaborations and Partnerships

Veonet Acquisition: Miranza's integration into Veonet has enhanced its operational capabilities and market reach.

Magrabi Health Partnership: A strategic partnership with Magrabi Health in the UAE aims to elevate eye care standards in the region.

Operational Insights

Strategic Considerations

Market Position: Miranza holds a strong position in the Iberian ophthalmology market, with plans for further expansion.

Competitive Advantages: The company's integration into Veonet provides access to a broader network and resources, enhancing its service offerings.